A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONBTROLLED, MULTI-CENTRE STUDY EVALUATING THE EFFICACY AND SAFETY OF MITAPIVAT IN SUBJECTS WITH NON-TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA (ENERGIZE)
- Registry ID
- AG348-C-017
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- AGIOS PHARMACEUTICALS INC
- Start date
- 2025-06-11
- Last update
- 2021-04-13
Conditions
Related clinical trials
- AN OPEN-LABEL, DOSE-ESCALATION, DOSE-FINDING, AND PROOF-OF-CONCEPT TRIAL OF SP-420 IN SUBJECTS WITH TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA OR LOW-RISK MYELODYSPLASTIC SYNDROMES
- NOVEL TRANSPLANT STRATEGY FOR HIGH-RISK THALASSEMIA PATIENTS A PHASE I/II TRAIL OF EARLY FLUDARABINE FOLLOWED BY ABATACEPT AND SIROLIMUS IMMUNOSUPPRESSION (THAL-FABS STUDY)
- A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OFMITAPIVAT IN SUBJECTS WITH TRANSFUSION-DEPENDENT ALPHA OR BETA-THALASSEMIA (ENERGIZE-T)
- A PHASE 2, OPEN-LABEL, MULTICENTER STUDY TO DETERMINE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF AG-348 IN ADULT SUBJECTS WITH NON-TRANSFUSION-DEPENDENT THALASSEMIA
- A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS PLACEBO IN ADULTS WHO REQUIRE REGULAR RED BLOOD CELL TRANSFUSIONS DUE TO BETA ()-THALASSEMIA
View on source registry